CytomX Therapeutics (Nasdaq: CTMX) Announces 2025 Financial Results and Key Business Updates

Key Highlights for Investors

• Positive Clinical Data: Encouraging results from the Phase 1 dose expansion study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY^® ADC in patients with advanced colorectal cancer (CRC) were announced.
• Regulatory Progress: CytomX is targeting FDA interactions mid-2026 to align on a potential registrational trial design for Varseta-M in late-line CRC.
• Pipeline Expansion:
  • Phase 1 combination study of Varseta-M with bevacizumab in CRC has been initiated.
  • Phase 1b/2 study combining Varseta-M with bevacizumab and chemotherapy expected to start by end of 2026.
  • Plans for additional Phase 1 expansion cohorts in other EpCAM-expressing tumor types in the second half of 2026.
• Exciting Progress in Immunotherapy:
  • Initial proof-of-concept data for CX-801 (PROBODY Interferon-alpha-2b) in combination with KEYTRUDA^® for advanced melanoma expected by end of 2026.
  • Monotherapy dose escalation reached the fourth dose level, with favorable safety profile above approved IFN-α2b doses.
  • Biomarker data from CX-801 presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, reinforcing the mechanism of action and supporting ongoing combination trials.
• Strong Financial Position:
  • Year-end 2025 cash, cash equivalents, and investments of \$137.1 million, providing a cash runway into Q2 2027.
• Collaboration Developments:
  • Ongoing research partnerships with Bristol Myers Squibb, Amgen, Regeneron, and Moderna, focusing on bispecific immunotherapies and T-cell engagers.
  • Astellas terminated its preclinical research collaboration, effective Q2 2026.

Detailed Business and Pipeline Update

Varsetatug Masetecan (“Varseta-M”, CX-2051): EpCAM PROBODY Topo-1 ADC

• Positive Phase 1 data in advanced CRC supports continued development. The company’s 2026 priority is FDA alignment on registrational study design for Varseta-M in late-line CRC.
• Additional follow-up data expected at major medical meetings in 2026.
• Combination studies with bevacizumab underway, with a Phase 1b/2 study (bevacizumab + chemotherapy) to start by year-end 2026.
• Planned initiation of expansion cohorts in other EpCAM-expressing cancer types in 2H 2026, highlighting potential for broader use.

CX-801 (PROBODY Interferon alpha-2b): Immunotherapy Program

• Monotherapy dose escalation has surpassed the approved dose of unmodified IFN-α2b, with good tolerability.
• Combination dose escalation with KEYTRUDA^® is ongoing (second dose level enrolling). Initial data in advanced melanoma are anticipated by end of 2026.
• Biomarker and translational data from monotherapy and combination studies show promising activity and support further advancement.

Financial Results (Year Ended December 31, 2025)

• Total Revenue: \$76.2 million (down from \$138.1 million in 2024, mainly due to completion of obligations in the Bristol Myers Squibb collaboration and lower collaboration milestone recognition with Moderna, Astellas, and Regeneron).
• Total Operating Expense: \$98.6 million (down from \$113.1 million in 2024).
• Research & Development Expense: \$68.7 million (down from \$83.4 million), reflecting the impact of January 2025 restructuring, lower general R&D, and reduced CX-904 spend, partly offset by increased Varseta-M costs.
• General & Administrative Expense: \$29.8 million (flat year-over-year), including \$1.1 million one-time restructuring charges.
• Net Loss Attributable to Common Stockholders: \$(20.4) million, compared to net income of \$31.9 million in 2024.
• Cash, Cash Equivalents, and Investments: \$137.1 million at year-end, up from \$100.6 million in 2024, supporting operations into Q2 2027.

Balance Sheet Highlights

• Total Assets: \$151.6 million (2025) vs. \$120.5 million (2024).
• Total Liabilities: \$52.6 million (2025) down sharply from \$121.0 million (2024) due to a decrease in deferred revenue.
• Equity: Shareholders’ equity rebounded to \$99.0 million from a deficit of \$0.5 million in 2024, driven by capital raises and disciplined expense management.

Strategic and Price Sensitive Developments

• Phase 1 Data for Varseta-M in CRC: Positive results may drive investor confidence and are a key value inflection point, given the potential for registrational trials.
• Cash Runway: Cash position supports operations until at least Q2 2027, reducing near-term financing risk.
• Major Collaborations: Continued partnerships with industry leaders (Bristol Myers Squibb, Amgen, Regeneron, Moderna) are a validation of CytomX’s technology platform.
• Astellas Collaboration Termination: While a minor setback, the core pipeline and major collaborations remain robust; investors should monitor for any impacts on future revenue streams.
• Upcoming Data Catalysts: Proof-of-concept data for CX-801/KEYTRUDA^® in melanoma and additional Varseta-M studies represent significant upcoming catalysts that could materially affect share value.

About CytomX Therapeutics

CytomX is a clinical-stage, oncology-focused biopharmaceutical company pioneering conditionally activated, masked PROBODY^® therapeutics. Its pipeline includes antibody-drug conjugates, cytokines, and T-cell engagers, with lead programs in metastatic colorectal cancer and melanoma. The company has established strategic collaborations with leading pharmaceutical companies to develop innovative cancer treatments.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with financial advisors before making any investment decisions. The information herein reflects the company’s disclosures as of March 16, 2026. All forward-looking statements are subject to risks and uncertainties as detailed in CytomX’s official filings with the U.S. SEC.

View CytomX Therapeutics, Inc. Historical chart here